Spectral Diagnostics Inc. (OTCMKTS:EDTXF – Get Free Report)’s stock price dropped 0.3% during mid-day trading on Wednesday . The company traded as low as $0.9830 and last traded at $0.9830. Approximately 21,191 shares were traded during trading, an increase of 187% from the average session volume of 7,392 shares. The stock had previously closed at $0.9860.
Spectral Diagnostics Trading Down 0.3%
The company has a market cap of $288.56 million, a P/E ratio of -9.83 and a beta of 0.11. The business’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $0.99.
Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The firm had revenue of $0.64 million during the quarter, compared to the consensus estimate of $0.54 million.
About Spectral Diagnostics
Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.
Featured Stories
- Five stocks we like better than Spectral Diagnostics
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
